Blogger's Note: older studies have also included efficacy in clear cell ovarian tumors
Abstract
PURPOSE:
The
standard regimen for platinum-resistant/refractory recurrent epithelial
ovarian cancer (EOC) remains to be determined. In this study, we
retrospectively compared the effect of irinotecan (CPT-11) and pegylated
liposomal doxorubicin (PLD) in the treatment of platinum-resistant
recurrent EOC.
METHODS:
Thirty patients who received
salvage chemotherapy with CPT-11 or PLD were included in the study.
CPT-11 (100 mg/m2) was administered intravenously on days 1, 8 and 15
every four weeks. PLD (50 mg/m2) was administered on day 1 every four
weeks. Treatment was repeated, provided that no disease progression or
intolerable toxicity occurred.
RESULTS:
Response rate in
the CPT-11 group and PLD group showed no difference at 26.7%
in both, while non-PD rate was 73.3% vs. 33.3%,
respectively. Progression-free survival after CPT-11 treatment and PLD
treatment was 28.4 weeks and 16.8 weeks, respectively.
Hand-foot syndrome and mucositis were more common in the PLD group than
in the CPT-11 group.
CONCLUSIONS:
The results indicate that CPT-11 is a promising drug for the treatment of platinum-resistant recurrent EOC.
